Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype

Seung Tae Lee; Joon Ho Jang; June Won Cheong; Jin Seok Kim; Ho Young Maemg; Jee Sook Hahn; Yun Woong Ko; Yoo Hong Min

doi:10.1046/j.1365-2141.2002.03767.x

Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype

Seung Tae Lee, Joon Ho Jang, June Won Cheong, Jin Seok Kim, Ho Young Maemg, Jee Sook Hahn, Yun Woong Ko, Yoo Hong Min

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

133 Citations (Scopus)

Abstract

A 20-year-old woman with high-risk acute myelogenous leukaemia was transplanted with granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood CD34⁺ haematopoietic stem cells and bone-marrow-derived mesenchymal stem cells (MSC) from her human leucocyte antigen haplotype-mismatched father after myeloablative conditioning therapy. The patient engrafted rapidly and had no acute or chronic graft-versus-host disease. Since transplantation, the patient has shown an enduring trilineage haematological complete response without any evidence of leukaemia relapse at 31 months. We suggest that MSC can be used effectively for genetically haploidentical haematopoietic stem cell transplantation for acute leukaemia.

Original language	English
Pages (from-to)	1128-1131
Number of pages	4
Journal	British Journal of Haematology
Volume	118
Issue number	4
DOIs	https://doi.org/10.1046/j.1365-2141.2002.03767.x
Publication status	Published - 2002

All Science Journal Classification (ASJC) codes

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1046/j.1365-2141.2002.03767.x

Fingerprint

Dive into the research topics of 'Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype'. Together they form a unique fingerprint.

Cite this

Lee, S. T., Jang, J. H., Cheong, J. W., Kim, J. S., Maemg, H. Y., Hahn, J. S., Ko, Y. W., & Min, Y. H. (2002). Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. British Journal of Haematology, 118(4), 1128-1131. https://doi.org/10.1046/j.1365-2141.2002.03767.x

Lee, Seung Tae ; Jang, Joon Ho ; Cheong, June Won et al. / Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. In: British Journal of Haematology. 2002 ; Vol. 118, No. 4. pp. 1128-1131.

@article{f66598d0e9dc443496f28cfc24395b37,

title = "Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype",

abstract = "A 20-year-old woman with high-risk acute myelogenous leukaemia was transplanted with granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood CD34+ haematopoietic stem cells and bone-marrow-derived mesenchymal stem cells (MSC) from her human leucocyte antigen haplotype-mismatched father after myeloablative conditioning therapy. The patient engrafted rapidly and had no acute or chronic graft-versus-host disease. Since transplantation, the patient has shown an enduring trilineage haematological complete response without any evidence of leukaemia relapse at 31 months. We suggest that MSC can be used effectively for genetically haploidentical haematopoietic stem cell transplantation for acute leukaemia.",

author = "Lee, {Seung Tae} and Jang, {Joon Ho} and Cheong, {June Won} and Kim, {Jin Seok} and Maemg, {Ho Young} and Hahn, {Jee Sook} and Ko, {Yun Woong} and Min, {Yoo Hong}",

year = "2002",

doi = "10.1046/j.1365-2141.2002.03767.x",

language = "English",

volume = "118",

pages = "1128--1131",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

Lee, ST, Jang, JH, Cheong, JW, Kim, JS, Maemg, HY, Hahn, JS, Ko, YW & Min, YH 2002, 'Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype', British Journal of Haematology, vol. 118, no. 4, pp. 1128-1131. https://doi.org/10.1046/j.1365-2141.2002.03767.x

Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. / Lee, Seung Tae; Jang, Joon Ho; Cheong, June Won et al.
In: British Journal of Haematology, Vol. 118, No. 4, 2002, p. 1128-1131.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype

AU - Lee, Seung Tae

AU - Jang, Joon Ho

AU - Cheong, June Won

AU - Kim, Jin Seok

AU - Maemg, Ho Young

AU - Hahn, Jee Sook

AU - Ko, Yun Woong

AU - Min, Yoo Hong

PY - 2002

Y1 - 2002

N2 - A 20-year-old woman with high-risk acute myelogenous leukaemia was transplanted with granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood CD34+ haematopoietic stem cells and bone-marrow-derived mesenchymal stem cells (MSC) from her human leucocyte antigen haplotype-mismatched father after myeloablative conditioning therapy. The patient engrafted rapidly and had no acute or chronic graft-versus-host disease. Since transplantation, the patient has shown an enduring trilineage haematological complete response without any evidence of leukaemia relapse at 31 months. We suggest that MSC can be used effectively for genetically haploidentical haematopoietic stem cell transplantation for acute leukaemia.

AB - A 20-year-old woman with high-risk acute myelogenous leukaemia was transplanted with granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood CD34+ haematopoietic stem cells and bone-marrow-derived mesenchymal stem cells (MSC) from her human leucocyte antigen haplotype-mismatched father after myeloablative conditioning therapy. The patient engrafted rapidly and had no acute or chronic graft-versus-host disease. Since transplantation, the patient has shown an enduring trilineage haematological complete response without any evidence of leukaemia relapse at 31 months. We suggest that MSC can be used effectively for genetically haploidentical haematopoietic stem cell transplantation for acute leukaemia.

UR - http://www.scopus.com/inward/record.url?scp=0036050976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036050976&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2002.03767.x

DO - 10.1046/j.1365-2141.2002.03767.x

M3 - Article

C2 - 12199796

AN - SCOPUS:0036050976

SN - 0007-1048

VL - 118

SP - 1128

EP - 1131

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Lee ST, Jang JH, Cheong JW, Kim JS, Maemg HY, Hahn JS et al. Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. British Journal of Haematology. 2002;118(4):1128-1131. doi: 10.1046/j.1365-2141.2002.03767.x

Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this